Valo Therapeutics Oy (ValoTx), a Finland-based immunotherapy company, has appointed Marcella Origgi as chief executive officer. Ms Origgi joins the company from Johnson & Johnson Innovation and has extensive experience in the development and commercialisation of cancer immunotherapies. She will be based in Italy where ValoTx has a subsidiary. Her appointment follows ValoTx’s recent €19 million financing round that will enable the completion of a Phase 1b clinical trial of its lead tumour antigen-coated oncolytic virus candidate, PeptiCRAd-1, in Germany, Italy and Australia. At Johnson & Johnson, Ms Origgi was responsible for sourcing and advancing external innovation opportunities across oncology, immunology, rare diseases and advanced therapies.
Valo Therapeutics announced the appointment on 9 April 2025.
Copyright 2025 Evernow Publishing Ltd.